2m 2m 2m 2m 2m 2m 2m
BLOSSOMHILL THER (BLSM)
NASDAQ
$13.77-$1.07 (-7.21%)
Price as of Nov 13, 2026 1:52 PM EST- $471.7MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
BLOSSOMHILL THER (BLSM)
$13.77-$1.07 (-7.21%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$14.51
$16.10
$14.84
1-Year Range
$12.35
$26.82
$14.84
Latest Close$14.84
Change
-$1.28 (-8.63%)
Volume256,383
Market Cap$471.7M
Shares Outstanding31.8M
P/E (TTM)-3.30
Diluted EPS (TTM)-$4.49
Enterprise Value$246.8M
Information as of 11/12/2026
Company Profile
BLOSSOMHILL THERAPEUTICS INC
https://bhtherapeutics.com$471.7M
Market Cap
-$47.8M
Net Income
Sector: Healthcare
Industry: Biotechnology
10255 Science Center Drive, San Diego, CA, United States, 92121
(858) 732-3880BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Key Executives
- Geoff Oxnard
- Jingrong Jean Cui
- Yishan Li
- Jason A. Keyes
- Eugene Y. Rui
Current Ownership Distribution
- Other28.6M (98.43%)
- Mutual Funds455,565 (1.57%)
- Institutions0 (0.00%)
- Insiders0 (0.00%)